secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2026-05-22T12:00:37+00:00
Accession:  0001493152-26-024913
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma receives Nasdaq extension to Nov 16, 2026 to meet $1 minimum bid price
--------------------------------------------------------------------------------

- Received Nasdaq Staff letter on May 20, 2026 granting 180-day extension until Nov 16, 2026 for minimum bid price compliance.
- Previously received initial deficiency notice on Nov 20, 2025; initial 180-day period expired May 19, 2026.
- Company meets all other Nasdaq Capital Market initial listing requirements except for minimum bid price.
- No assurance of compliance; company will monitor bid price and assess options to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/0001493152-26-024913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-024913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer